Breast cancer is one of the most prevalent malignancies and the leading cause of cancer-associated mortality in China. Icaritin (ICT), a prenyl flavonoid derived from the Epimedium Genus, has been proven to inhibit the proliferation and stemness of breast cancer cells. Our previous study demonstrated that IC2, a derivative of ICT, could induce breast cancer cell apoptosis by Stearoyl-CoA desaturase 1 (SCD1) inhibition. The present study further investigated the mechanism of the inhibitory effects of IC2 on breast cancer cells in vitro and in vivo. Our results proved that IC2 could stimulate autophagy in breast cancer cells with the activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling and mitogen-activated protein kinase (MAPK) signaling. Combination treatment of the AMPK inhibitor decreased IC2-induced autophagy while it markedly enhanced IC2-induced apoptosis. In common with IC2-induced apoptosis, SCD1 overexpression or the addition of exogenous oleic acid (OA) could also alleviate IC2-induced autophagy. In vivo assays additionally demonstrated that IC2 treatment markedly inhibited tumor growth in a mouse breast cancer xenograft model. Overall, our study was the first to demonstrate that IC2 induced cytoprotective autophagy by SCD1 inhibition in breast cancer cells and that the autophagy inhibitor markedly enhanced the anticancer activity of IC2. Therefore, IC2 was a potential candidate compound in combination therapy for breast cancer.
G protein-coupled receptors (GPCRs) are significant drug targets, but their potential in cancer therapy remains underexplored. Conventional GPCR agonists or antagonists have shown limited effectiveness in cancer treatment, necessitating new GPCR-targeting strategies for more effective therapies. This study discovers that Yersinia pestis LcrV, a crucial linker protein for plague infection, acts as a biased agonist of a GPCR, the formyl peptide receptor 1 (FPR1). The LcrV protein induces unique conformational changes in FPR1, resulting in G proteins being activated in a distinctive state without subunit dissociation. This leads to a biased signaling profile characterized by cyclic adenosine monophosphate (cAMP) responses and β-arrestin2 recruitment, but not calcium mobilization. In FPR1-expressing triple-negative breast cancer (TNBC) cells, LcrV bi-directionally modulates intracellular signaling pathways, downregulating extracellular signal-regulated kinases (ERK1/2) and Akt pathways while upregulating Jun N-terminal kinase (JNK) and p38 pathways. This dual modulation results in cell cycle arrest and the inhibition of TNBC cell proliferation. In TNBC xenograft mouse models, long-term LcrV treatment inhibits tumor growth more effectively than a conventional FPR1 antagonist. Additionally, LcrV treatment reprograms tumor cells by reducing stemness-associated proteins OCT4 and c-MYC. Our findings highlight the potential of biased GPCR agonists as a novel GPCR-targeting strategy for cancer treatment.
Background: Clear cell renal cell carcinoma (ccRCC or KIRC) is a malignant neoplasm characterized by reprogrammed lipid metabolism. Fatty acid desaturase 3 (FADS3), a sphingoid Δ14Z desaturase, is required for the synthesis of unsaturated fatty acids in tumor biology. However, the role of FADS3 in ccRCC progression and prognosis and in modulating the tumor immune microenvironment (TIME) remains to be elucidated. Methods: The ccRCC transcriptomic datasets were obtained from the TCGA, GEO, and GTEx databases. Mendelian randomization (MR) and single-cell RNA sequencing analyses were used to investigate the associations of FADS3 with lipid metabolism, and differential expression genes in ccRCC. Bioinformatics analysis was also used to investigate the association of FADS3 expression with tumor progression, prognosis, TIME, and potential pathogenic mechanism in ccRCC. FADS3 expression in ccRCC cell lines was confirmed by qRT-PCR, western blotting, RNA-Seq. FADS3 roles in ccRCC were assessed by functional assays including cell proliferation, migration, invasion, and colony formation using wild-type and FADS3-knockdown cell lines. Results: Lipid metabolism was found to be upregulated in ccRCC tumor tissues based on comprehensive bioinformatic analysis. FADS3 was among the upregulated genes associated with lipid metabolism, which was expressed not only in ccRCC tumor cells but also in cells of the TIME, such as tumor-associated macrophages (TAMs). High FADS3 expression remodeled the TIME and predicted poor prognosis in ccRCC. Functional assays demonstrated that FADS3 knockdown markedly suppressed ccRCC cell proliferation, migration and invasion. Transcriptomic analyses further suggested that FADS3 may promote ccRCC progression through activation of oncogenic and metabolic signaling pathways, such as the PI3K/Akt pathway. Conclusion: FADS3 is a lipid metabolism-associated oncogenic driver in ccRCC, and its upregulation remodels the TIME and predicts poor prognosis. FADS3 may represent a potential therapeutic target for ccRCC treatment.
Secreted Phosphoprotein 1 (SPP1) was reported to promote the progression of multiple tumors by modulating the immune microenvironment and facilitating metastasis, but its role in cervical cancer remains unclear. Our purpose was to explore the effect and the potential mechanisms of SPP1 on cervical cancer progression and paclitaxel (PTX)-induced epithelial-mesenchymal transition (EMT). The Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) database were used to detect SPP1 expression in human cervical cancer and para-carcinoma non-tumor tissues, immunohistochemistry and western blotting experiments were carried out to confirm the expression of SPP1 in clinical samples. Cancer cell proliferation and metastasis assays were conducted to detect the effects of SPP1 on cancer progress using normal and SPP1-knockdown cervical cancer cells. Transcriptomics data and protein expression assays were utilized to investigate the mechanism underlying the effect of SPP1 on PTX-induced EMT. The mouse metastasis model was used to detect the effect of SPP1 on PTX-induced EMT during cervical cancer metastasis. SPP1 is highly expressed in cervical cancer clinical samples and is associated with low survival rates, SPP1 knockdown inhibits cervical cancer cell migration and invasion but doesn't affect cell proliferation. Further studies revealed that SPP1 knockdown suppresses tumor cell EMT through the TGF-β/Akt/Snail pathway. Both in vivo and in vitro data confirmed that SPP1 knockdown alleviates PTX-induced EMT. SPP1 knockdown inhibits the invasion, metastasis and PTX-induced EMT of cervical cancer by suppressing TGF-β/Akt/Snail signaling pathway, and SPP1 is a potential therapeutic target for cervical cancer treatment.